Donald K. Strickland

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer et al. · The Lancet Oncology · 2016 · 537 citations · Full text

Dll3-targeted Antibody-drug Conjugate, Medicine, Immunology +6

Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia

Wing Leung, Melissa M. Hudson, Donald K. Strickland et al. · Journal of Clinical Oncology · 2000 · 210 citations

The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort

Sharon M. Castellino, Shelly Lensing, Caroline A. Riely et al. · Blood · 2003 · 95 citations · Full text

Hepatitis C infection among survivors of childhood cancer

Donald K. Strickland, Caroline A. Riely, Christian C. Patrick et al. · Blood · 2000 · 86 citations

Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.

Steven Arkin, Francine Blei, James Fetten et al. · PubMed · 2000 · 70 citations

Novoseven Emergency-use Programme, Bleeding Episodes, Emergency-use Study +16